ReviewInternational journal of heart failure2020
Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis.
Review in International journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Bridging the Diagnostic Gap: Toward Non-Invasive Detection of Transthyretin Cardiac Amyloidosis in Acute Heart Failure.International journal of heart failure · 2025Article
- Poor Outcome of the p.Ser43AsnInternational journal of heart failure · 2025Article
- To see those not to be seen: cardiac uptake on noncardiac imaging.Journal of cardiovascular imaging · 2024Article
- Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study.Journal of Korean medical science · 2024Article
- Prognostic value of native T1 and extracellular volume in patients with immunoglubin light-chain amyloidosis.BMC cardiovascular disorders · 2024Article
- Temporal trends in the prevalence, incidence, and mortality of cardiac amyloidosis in Korea over 12 years.Epidemiology and health · 2024Article
- Optimization of guideline-directed medical treatment for heart failure patients with reduced ejection fraction.The Korean journal of internal medicine · 2023Review
- A Novel Transthyretin Gene Mutation in Hereditary Transthyretin Amyloidosis: A Case Series of Met13dup Patients.Korean circulation journal · 2023Article
- Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment.International journal of heart failure · 2023Review
- Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment.Korean circulation journal · 2023Review
- Multimodal Imaging and Biomarkers in Cardiac Amyloidosis.Diagnostics (Basel, Switzerland) · 2022Review
- Prognostic Implication of Longitudinal Changes of Left Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis.Frontiers in cardiovascular medicine · 2022Article
- Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis.ESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis (CA) is a highly underdiagnosed cause of heart failure. Amyloid light-chain (AL) and amyloid transthyretin (ATTR) cardiomyopathy are two major subtypes of cardiac amyloid. Amyloid fibril deposits cause cardiac dysfunction by mechanically infiltrating the myocardium or by direct cardiotoxicity. Achieving a timely diagnosis is important to initiate disease-modifying therapies and improve the survival of patients with CA. Therefore, physicians must be aware of "red flag symptoms" that increase suspicions for CA when assessing heart failure patients. Although endomyocardial biopsy is a definitive diagnostic tool, with recent advances in non-invasive imaging, non-biopsy diagnosis is feasible in ATTR CA. There have been major advances in treatments for both AL and ATTR CA, and survival of CA has improved. In addition to general management of heart failure, numerous treatment options are increasing for both AL and ATTR CA. Given the systemic nature of amyloids, multi-disciplined team approaches are crucial to management of CA. With recent development of diagnosis and treatment options for both AL and ATTR amyloidosis, it is no longer considered a non-treatable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.